Is the TScan Therapeutics (TCRX) investment thesis intact?

It is under pressure. Readouts currently rates the TScan Therapeutics Thesis Challenged. TScan paused its Phase 3 for lack of cash; preclinical TCR-T programs remain.

What is the next catalyst for TScan Therapeutics (TCRX)?

The next dated event is Phase 1 interim results (ALLOHA) for TSC-101, expected Q4 2026, as stated by the company. Also ahead: Preclinical results for PRAME/MAGE-A4 in vivo TCR-T, expected Q1 2027.

How long will TScan Therapeutics' cash last?

TScan Therapeutics has said its cash will fund operations into Q4 2027 (guidance as of September 2, 2026).

TCRXTScan Therapeutics, Inc.

Market reactionShares fell 13% on Nov 5.

ChallengedLast material event Sep 2, 2026 · Updated Oct 25, 2026

TScan paused its Phase 3 for lack of cash; preclinical TCR-T programs remain

TScan Therapeutics develops engineered T cell therapies for cancer. It has paused its blood cancer program and now focuses on preclinical solid tumor candidates; none of its products is approved.

TScan's original case was TSC-101, given to prevent relapse after stem cell transplant. In September TScan paused the Phase 3 ALLOHA-2 trial for lack of capital, after 7 patients were treated. It cut about 75% of its staff and is seeking partners for its blood cancer and autoimmune programs. What remains are two preclinical in vivo TCR-T candidates for solid tumors, targeting PRAME and MAGE-A4. Preclinical data are due in early 2027, with an IND and Phase 1 start later that year.

Thesis checklist

1 risk needs attention

Select a row for evidence

What must be trueStateNext proof

In vivo TCR-T candidates show convincing preclinical dataAwaiting evidencePreclinical data (first quarter of 2027).Next: Preclinical data (first quarter of 2027).

Why it is in this state

The evidence, what would weaken it and the source filing

First solid tumor IND goes in on scheduleAwaiting evidenceIND submission (third quarter of 2027).Next: IND submission (third quarter of 2027).

Why it is in this state

The evidence, what would weaken it and the source filing

A partner takes on the paused TSC-101 programAwaiting evidenceCohort C update (fourth quarter of 2026).Next: Cohort C update (fourth quarter of 2026).

Why it is in this state

The evidence, what would weaken it and the source filing

Cash lasts until Phase 1 startsAt riskQ3 2026 cash balance.Next: Q3 2026 cash balance.

Why it is in this state

The evidence, what would weaken it and the source filing

Next decision point

Preclinical data on the in vivo TCR-T candidates

Tests: In vivo TCR-T candidates show convincing preclinical data

First quarter of 2027

Do the PRAME and MAGE-A4 candidates engineer T cells inside the body that kill tumors selectively in preclinical models?

Strong, inconclusive and weak outcomes

What to look for in the result and how each would move the checklist

Questions to investigate

History

Price and material events

Select an event marker to read the update below. Marker colors show Thesis status.

ChallengedCurrentClinical

-42.8%Sep 2, 2026

TScan paused its Phase 3 for lack of cash; preclinical TCR-T programs remain

ChallengedCorporate

-9.1%Aug 12, 2026

ALLOHA-2 enrolls on strong chimerism data, but Amgen's exit and a Q2 2027 cash runway reframe the survival bet

IntactClinical

+6.5%Jun 22, 2026

TSC-101 enters Phase 3 ALLOHA-2 in AML/MDS post-HCT; pivotal RFS data will determine whether Phase 1 signals translate to registrational benefit

IntactClinical

-36.1%Nov 3, 2025

PLEXI-T solid tumor enrollment paused; program de-prioritized

About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.

Pipeline

Solid tumors

PRAME/MAGE-A4 in vivo TCR-T · 3 upcoming

Data

Q1 2027

IND Submission

Q3 2027

Phase 1 Study Initiation

Q4 2027

Hematologic malignancies· post-HCT

TSC-101 · 2 upcoming

Phase 1 Data: InterimALLOHA

Q4 2026

Phase 1 Data: Long-termALLOHA

Q2 2027

Acute myeloid leukemia· MDS · post-HCT

TSC-101 · 2 completed

Study InitiationPivotal

Jul 1, 2026

IND Submission

Reported Mar 4, 2026

Solid tumors

PLEXI-T · 1 completed

Data: InterimPLEXI-TDiscontinued

Reported Mar 4, 2026

Acute myeloid leukemia· ALL · MDS post-HCT

TSC-101 · 1 completed

Phase 1 Data: Long-termALLOHA

Dec 1, 2024

Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.

Quick answers

Is the TScan Therapeutics (TCRX) investment thesis intact?: It is under pressure. Readouts currently rates the TScan Therapeutics Thesis Challenged. TScan paused its Phase 3 for lack of cash; preclinical TCR-T programs remain.
What is the next catalyst for TScan Therapeutics (TCRX)?: The next dated event is Phase 1 interim results (ALLOHA) for TSC-101, expected Q4 2026, as stated by the company. Also ahead: Preclinical results for PRAME/MAGE-A4 in vivo TCR-T, expected Q1 2027.
How long will TScan Therapeutics' cash last?: TScan Therapeutics has said its cash will fund operations into Q4 2027 (guidance as of September 2, 2026).

Disease areas: Blood cancers, Other cancers, Autoimmune and inflammatory diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes

Competitive landscape

9 peers tracked

Financial snapshot

Dates and calculation details

Cash: Market-data provider estimate; measurement period unavailable.

Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.

Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.

Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.

Runway: No underlying guidance available.